# Precision (DTIL) — News DTIL · NASDAQ · Stock Canonical page: https://www.lighthorse.io/tickers/dtil/news ## Recent headlines - [Precision Biosciences - initial safety data from Function-DMD trial targeted for year-end 2026 - SEC filing](https://www.ainvest.com/news/precision-biosciences-initial-safety-data-function-dmd-trial-targeted-year-2026-sec-filing-2607) — AInvest Wire, Jul 1, 2026 Precision BioSciences, Inc. (Nasdaq: DTIL) is advancing its Phase 1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, a first-in-class in vivo gene editing therapy for Duchenne muscular dystrophy (DMD). The trial, which began enrolling patients at Arkansas Children’s Hospital in April 2026, is designed… - [Precision Biosciences - extends term loan maturity date to December 31, 2029 - SEC filing](https://www.ainvest.com/news/precision-biosciences-extends-term-loan-maturity-date-december-31-2029-sec-filing-2606) — AInvest Wire, Jun 16, 2026 Precision BioSciences, Inc. (Nasdaq: DTIL) has filed a report with the U.S. Securities and Exchange Commission (SEC) indicating that it has extended the maturity date of its term loan to December 31, 2029. The filing, dated June 5, 2026, is part of the company’s changes in beneficial ownership .… - [Precision Biosciences Inc : Oppenheimer initiates coverage with outperform rating; price target $20](https://www.ainvest.com/news/precision-biosciences-dtil-oppenheimer-initiates-coverage-outperform-rating-price-target-20-2606) — AInvest Wire, Jun 9, 2026 Precision Biosciences Inc (DTIL.O) has recently drawn attention following Oppenheimer's initiation of coverage with an "outperform" rating and a price target of $20 per share. The stock closed at $8.16 on June 8, 2026, reflecting a 5.23% decline from the previous day's close, although it has since… - **Important** — [Hon Hai Precision Industry (Foxconn) announced a strategic cooperation with Intel (INTC.O) to jointly develop an AI platform](https://www.ainvest.com/news/hon-hai-precision-industry-foxconn-announced-strategic-cooperation-intel-intc-jointly-develop-ai-platform-2606) — AInvest Wire, Jun 4, 2026 - **Important** — [Precision Biosciences: FDA fast track designation PBGene-DMD](https://www.ainvest.com/news/precision-biosciences-fda-fast-track-designation-pbgene-dmd-2603) — AInvest Wire, Mar 9, 2026 --- Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express. This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness. Data provided by [AInvest](https://www.ainvest.com).